Invesco S&P 500 Equal Weight (RSP) Adds Vylor and Moderna on Nov. 5

Invesco's S&P 500 Equal Weight ETF (RSP) bought $976.9M in stocks on Nov. 5, including new positions in Vylor (VYLR) and small top-ups in Moderna (MRNA) and PTC (PTC). The fund holds 503 stocks with $101.82B in assets, focusing on large-cap U.S. equities. RSP has a 0.2% expense ratio, a P/E of 20.52, and a 14.13% YTD return.

Original reporting
Published Nov 9, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Invesco S&P 500 Equal Weight (RSP) Adds Vylor and Moderna on Nov. 5 — source image
Decision brief

The 30-second read

$VYLRBullishLow
01

Why it matters

The disclosed purchases provide insight into short‑term demand for the listed stocks, especially the sizable new position in Vylor.

02

Market read

Fund buying activity can move small‑cap stocks and offers a snapshot of sector allocation trends.

03

What to watch

Potential hidden exposure to sector rotation or upcoming earnings that could reverse the short‑term pressure.

Relevance 4/10Novelty 4/10Timing: today

Background

Invesco's S&P 500 Equal Weight ETF reported its daily trading activity, highlighting new positions and purchases.

Company-level read

Ticker impact

$VYLRBullishHigh confidence
Context

Invesco S&P 500 Equal Weight ETF added a new $190.1 million position in Vylor Inc, its largest buy of the day.

Expected impact

likely upward pressure as the market prices in the large fund purchase

Evidence & confidence

A $190 M new position by a $101 B ETF is material for a small‑cap stock.

$MRNANeutralMedium confidence
Context

The ETF increased its holding of Moderna Inc by 11,648 shares worth $2.8 million.

Expected impact

slight upward pressure due to incremental fund buying

Evidence & confidence

The purchase size is small relative to Moderna’s market cap.

$PTCNeutralMedium confidence
Context

The ETF added 12,012 shares of PTC Inc, a $2.3 million purchase.

Expected impact

minimal upward impact as the trade is modest

Evidence & confidence

The trade is small but adds to the ETF’s exposure.

$NVRNeutralLow confidence
Context

The ETF bought 364 shares of NVR Inc, a $2.3 million purchase.

Expected impact

little to no price effect

Evidence & confidence

The dollar amount is tiny for a large‑cap homebuilder.

$ACNNeutralLow confidence
Context

The ETF added 8,736 shares of Accenture PLC, a $2.3 million purchase.

Expected impact

little to no price effect

Evidence & confidence

Accenture is a large cap; the trade is insignificant.

Market effects

The fund’s increased weighting in technology and healthcare may slightly boost sector sentiment.

US equity market sees modest inflows from the ETF’s activity.

Limited to US markets; no broader macro impact.

Counterpoint

The fund’s buying may be a contrarian signal if the stocks are overbought.

Key entities

  • Invesco S&P 500 Equal Weight ETF

    Fund with $101.82 B in assets that made the disclosed trades.

Related articles

$MRNAMed

Why is Moderna stock sliding today?

Moderna (MRNA) shares fell 3.8% to $212.50 as investors reassess its valuation after its 2026 Analyst Day. The company projected higher cash costs and deferred 2027 revenue guidance, disappointing investors. A norovirus vaccine trial also failed to meet early success criteria. Insider stock sales and a weak market for growth equities added to the pressure, though Moderna will be added to the MSCI World Index on November 30.

$MRNAMed

Moderna Sinks 12% in a Week. Bancel Wants an FDA Filing “Before the End of the Year”

Moderna (MRNA) fell 12% in the week to Nov. 13 after projecting $4B+ annual costs through 2030, primarily for cancer drug development, including intismeran with Merck (MRK). CEO Bancel aims for FDA filing by year-end. Analysts' 2028 revenue estimates are below annual costs, and the stock trades at a high sales multiple. BioNTech (BNTX), a rival, expects revenue to fall 35.4% this year.

$VYLRMedAI 8/10

Vylor Earnings Call Highlights Growth Amid Near-Term Headwinds

Vylor Inc (VYLR) reported Q3 earnings with year-to-date revenue up 4% to $8.5B and EBITDA up 8% to $2.7B. Despite a Q3 EBITDA loss, management highlighted growth in licensing, margins, and market share. Challenges included weather-related volume pressure, higher costs, and Brazil financing conditions. The company completed its separation on time and under budget.

$MRKMedAI 9/10

He Has Had Surgery for Melanoma and Is Terrified the Cancer Will Return. A New Vaccine Kept 82% of Trial Patients Cancer-Free for Two Years, but Medicare Won’t Pay for Experimental Treatment

Merck (MRK) and Moderna (MRNA) reported a Phase 3 trial where a personalized vaccine, combined with Keytruda, kept 82.2% of melanoma patients cancer-free for two years, compared to 70.0% with Keytruda alone. The vaccine is not yet FDA-approved, so Medicare does not cover it outside of clinical trials. Patients may face out-of-pocket costs for trial participation.